The products and information provided on this website are intended for healthcare professionals. These products are not for sale or distribution in the United States and statements made regarding these products have not been evaluated by the U.S. Food and Drug Administration (FDA). The efficacy of these products has not been confirmed by FDA-approved research and these products are therefore not intended to diagnose, treat, cure or prevent any disease. All information presented here is for general information purposes only and not meant as a substitute for or alternative to advice from healthcare practitioners. The Federal Food, Drug and Cosmetic Act requires this notice.
Sudden Cardiac Arrest – Doc Fischer talks about CARL. in SWR-TV
It can happen to anyone at any time. Around 65,000 people in Germany suffer from cardiac arrest every year. The time and duration of resuscitation efforts are crucial factors that directly impact the chances of neurologically intact survival.
The SWR-health programme ‘Doc Fischer’ explains the causes of sudden cardiac arrest and how the new CARL-Therapy can improve survival rates, both in- and out-of-hospital.
Prof. Georg Trummer from the Medical Center – University of Freiburg, and Prof. Christoph Benk, Chief Technology Officer at Resuscitec, explain the advanced extracorporeal circulation therapy developed specifically for resuscitation use.
20 years of research and development result into a unique ad hoc patient-monitoring of relevant vital parameters to perform a patient-individualized, controlled and automated reperfusion of the whole body. For patients, this means an improved chance of neurologically intact survival after refractory cardiac arrest.